The short version of alpha-MSH analogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-14. Anything still debated is marked as such rather than presented as settled.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
The fruit is a hairy pod that grows in clusters of three to five, each pod is 3–8 cm (1–3 in) long and usually contains two to four (rarely more) seeds 5–11 mm in diameter. Soybean seeds come in a wide variety of sizes and hull colors such as black, brown, yellow, and green. Variegated and bicolored seed coats are also common.
== Applications == Ion exchange is widely used in the food and beverage industry, hydrometallurgy, metals finishing, chemical, petrochemical, pharmaceutical technology, sugar and sweetener production, ground- and potable-water treatment, nuclear, softening, industrial water treatment, semiconductor, power, and many other industries. A typical example of application is preparation of high-purity water for power engineering, electronic and nuclear industries; i.e. polymeric or inorganic insoluble ion exchangers are widely used for water softening, water purification, water decontamination, etc. Ion exchange is a method widely used in household filters to produce soft water for the benefit of laundry detergents, soaps, and water heaters. This is accomplished by exchanging divalent cations (such as calcium Ca2+ and magnesium Mg2+) with highly soluble monovalent cations (e.g., Na+ or H+) (see water softening). Another application for ion exchange in domestic water treatment is the removal of nitrate and natural organic matter. In domestic filtration systems ion exchange is one of the alternatives for water softening in households along with reverse osmosis (RO) membranes. Compared to RO membranes, ion exchange requires repetitive regeneration when inlet water is hard (has high mineral content). Industrial and analytical ion-exchange chromatography is another area to be mentioned. Ion-exchange chromatography is a chromatographical method that is widely used for chemical analysis and separation of ions.
Yvonne Frances Rawsthorne. Operational Readiness Senior Officer, HM Revenue and Customs. For Public Service. Iain Robert Reeve. Head of Ukraine Rail Response Team, Department for Transport. For services to Rail Aid in Ukraine. Carole Patricia Richardson. Lately Chair, Rossie Young People's Trust. For services to Young People. Dr. Gordon Cameron Richardson. Treasurer, Walking Alliance. For services to Disability Access. Luke Thomas Rigg, JP. Lead Diversity and Community Relations Magistrate for England and Wales. For services to Diversity in the Judiciary. Gaynor Jean Ripley. Partnership Manager, Department for Work and Pensions. For Public Service. Fiona Roberts, JP. Magistrate, Cornwall Bench, South West Region. For services to the Magistracy and the Administration of Justice. Kathryn Rose Roberts. Chief Executive Officer, Association of Mental Health Providers. For services to Mental Health. Elaine Linda Robinson. Founder Member, Parents of Oldham InTouch and Oldham Special Educational Needs and Disabilities Support Service. For services to Children with Special Educational Needs and Disabilities. Lesley Robinson. Managing Director, First Class Supply and Tutoring Ltd. For services to Education. Rebecca Robson. Founder, Women's Community Matters. For services to the Victims of Domestic Abuse. Simon Rogan. Chef, L'Enclume. For services to the Food Industry. Patricia Mary Rogers. Co-Founder, Every Action Has Consequences. For services to Young People. Samuel Ross. Artist, Designer and Creative Director. For services to Fashion. Ian Alexander Russell.
An example CLIA ID number is 21D0665373, the CLIA Certificate of Accreditation (CoA) for the National Institutes of Health (NIH) Department of Laboratory Medicine (DLM) located in Bethesda, Maryland. Laboratories that are CLIA-exempt and those designated as VA laboratories do not have a CLIA certificate, but are assigned a CLIA identification number. Once a laboratory is assigned a number, it retains this number even if it withdraws from CLIA, has its certificate revoked, changes its certificate type or ownership, location (i.e., relocates to another State), name, or operator. A CLIA number will not be reassigned to another laboratory. Although CLIA-exempt laboratories do not need a CLIA certificate to operate, they are assigned a CLIA identification number for Medicare and Medicaid payment purposes.
== Protection & Formation == Fmoc-carbamate is frequently used as a protecting group for primary and secondary amines, where the Fmoc group can be introduced by reacting the amine with fluorenylmethyloxycarbonyl chloride (Fmoc-Cl), e.g.:
Sources: en.wikipedia.org
Early surgical techniques like iridectomy and fistulating methods have recently been supplemented by less invasive procedures like small implants, a range of options now widely called MIGS (micro-invasive glaucoma surgery).
Type V – Having the same clinical features as type IV, it can be clinically distinguished by observing a "mesh-like" appearance to a bone biopsy under a microscope. Type V can be further distinguished from other types of OI by the "V triad": an opaque band (visible on X-ray) adjacent to the growth plates; hypertrophic calluses (abnormally large masses of bony repair tissue) which form at fracture sites during the healing process; and calcification of the interosseous membrane of the forearm, which may make it difficult to turn the wrist. Other features of this condition may include pulled elbow, and, as in other types of OI, long bone bowing and hearing loss. Cases of this type are caused by mutations in the IFITM5 gene on chromosome 11p15.5. The separation of type V from type IV OI, its clinical type, was initially suggested even before its genetic cause was known, by Glorieux et al. in 2000. Type V is relatively common compared to other genetically defined types of OI—4% of OI patients at the genetics department of the Brazilian Hospital de Clínicas de Porto Alegre were found to have it. Type VI – With the same clinical features as type III, it is distinguished by bones which have an appearance similar to that seen in osteomalacia. Type VI is caused by a loss-of-function mutation in the SERPINF1 gene on chromosome 17p13.3. Type VII – OI caused by a mutation in the gene CRTAP on chromosome 3p22.3; clinically similar to OI types II and III, depending on affected individual.
Stirring of a given sample of amylose is said to form fibrillar crystals which are said to precipitate out of the mother liquor. These long fibrils can be imaged using electron microscopy revealing transverse striations resembling a shish-kebab. Amylose fibrils are categorized with having one of two morphologies: ones with small rodlike fibrils and others with lath-shaped crystals.
While SR-17018 produced little to no analgesic tolerance in the hot plate test, subsequent research using other rodent pain models found that it did produce tolerance in the warm water tail immersion assay and to a similar degree as morphine and oxycodone. Moreover, both SR-17018 and morphine showed cross-tolerance with each other in this test. Both morphine and SR-17018 tolerance in the test could be partially reversed by a protein kinase C (PKC) inhibitor. Based on these findings, it was concluded that a single analgesic test may be inadequate for assessing a drug's analgesic tolerance. However, a later study found that SR-17018 produced analgesic tolerance, albeit slightly delayed, in the hot plate test as well. In addition to the preceding findings, whereas SR-17018 reversed morphine analgesic tolerance in the hot plate test, it did not do so in the tail flick assay. On the other hand, chronic SR-17018 administration maintained efficacy in the formalin paw-withdrawal assay and paclitaxel-induced neuropathic pain model, showing no tolerance in these tests, whereas morphine and oxycodone caused tolerance in these assays. In a subsequent study to its initial in-vitro characterization, it was found that SR-17018 showed low activational efficacy across a selection of MOR signaling pathways, whereas classical opioids like morphine, fentanyl, methadone, and oxycodone showed higher efficacy.
Amphotericin B is an antifungal medication used for serious fungal infections and leishmaniasis. The fungal infections it is used to treat include mucormycosis, aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, and cryptococcosis. It is sometimes used as a drug of last resort for primary amoebic meningoencephalitis. For certain infections it is given with flucytosine. It is typically given intravenously. Common side effects include a reaction with fever, chills, and headaches soon after the medication is given, as well as kidney problems. Allergic symptoms including anaphylaxis may occur. Other serious side effects include low blood potassium and myocarditis (inflammation of the heart). It appears to be relatively safe in pregnancy. There is a lipid formulation that has a lower risk of side effects. It is in the polyene class of medications and works in part by interfering with the cell membrane of the fungus. Amphotericin B was isolated from Streptomyces nodosus in 1955 at the Squibb Institute for Medical Research from cultures isolated from the streptomycete obtained from the river bed of Orinoco in that region of Venezuela and came into medical use in 1958. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.